Clinical Evaluation of Genetically Engineered Hypoallergenic rBet v 1 Derivatives

Publisher： Karger

E-ISSN： 1423-0097|118|2-4|216-217

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.118, Iss.2-4, 1999-04, pp. : 216-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite

Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model

By  

ALLERGY, Vol. 70, Iss. 12, 2015-12 ,pp. : 1559-1568

John Wiley & Sons Inc

Access to resources Recommend Favorite

Induction of Blocking Antibodies with T Cell Epitope-Containing Hypoallergenic Recombinant Bet v 1 Fragments

By  

International Archives of Allergy and Immunology, Vol. 124, Iss. 1-3, 2012-01 ,pp. : 107-108

Karger

Access to resources Recommend Favorite

Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

By  

International Archives of Allergy and Immunology, Vol. 145, Iss. 3, 2007-10 ,pp. : 193-206

Karger

Access to resources Recommend Favorite

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 1, 2005-09 ,pp. : 59-66

Karger

Access to resources Recommend Favorite